Capricor, Nippon Shinyaku enter commercialization, distribution partnership

Capricor Therapeutics has entered into a partnership with Nippon Shinyaku for the exclusive commercialization and distribution in Japan of Capricor’s lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy, a rare neuromuscular disease with limited treatment options. This follows the exclusive Commercialization and Distribution Agreement entered into with Nippon Shinyaku in the United States in January 2022 Under the terms of the agreement, Capricor will receive an upfront payment of $12M and in addition, Capricor will potentially receive additional development and sales-based milestone payments of up to approximately $89M and a meaningful, double-digit share of product revenue. This agreement is similar to the terms of the U.S. agreement with Nippon Shinyaku, in that Capricor will be responsible for clinical development and Nippon Shinyaku will be responsible for the distribution of CAP-1002 in Japan, once approved. Capricor will sell commercial product to Nippon Shinyaku. In addition, Capricor will hold the Marketing Authorization in Japan, if the product is approved in that territory.